AI PRICE FORECAST
EW Stock Forecast & AI Price Prediction
Edwards Lifesciences · Healthcare · Medical Devices
EW live signal snapshot
EW last traded at $105.81, up 1.73% on the session, trading within 0.2% of its 52-week high of $106.04. Stock Pulse 247's AI model currently rates EW a BUY, at 87% model confidence. Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $109.37 (3.4% from here).
On the 14-day relative strength index, EW reads 86.4, above the 70 line traders treat as overbought, so a breather would not be unusual. Its MACD line is above its signal line with a positive histogram (1.42) — upward momentum is accelerating. Its 50-day average ($89.78) is holding 4.3% above the 200-day ($86.09), the pattern chartists call a golden cross.
The average 12-month target from 27 Wall Street analysts is $112.42 (range $84.00–$126.00) — 6.2% upside from where EW trades now. The current recommendation trend leans bullish: 25 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 4 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive EW dashboard for numbers updated throughout today's session.
About Edwards Lifesciences
Edwards Lifesciences Corporation (EW) is a medical devices company in the healthcare sector, headquartered in Irvine, CA, United States. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It has a market value of about $60.8 billion and roughly 16,000 full-time employees. Its beta of 0.83 means it has historically moved roughly in line with the market.
EW performance vs. the market
Year to date, EW has gained 24.1%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 25.8%, 14.3 points better than the S&P 500. The last month (+24.1%) continues the three-month advance (+14.3%).
| Period | EW | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +24.1% | +11.4% | −2.3% |
| 3 months | +14.3% | +12.2% | −2.3% |
| Year to date | +24.1% | +22.1% | +11.4% |
| 1 year | +25.8% | +28.3% | +11.5% |
Edwards Lifesciences financials at a glance
In the quarter ended Sep 30, 2026, Edwards Lifesciences reported revenue of $1.7 billion and net income of $308 million (a 17.9% net margin). Revenue was up 10.5% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 61.5 on trailing earnings of $1.72 per share. Trailing free cash flow was $1.1 billion, and total debt equals 6% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $1.7B | $308M |
| Jun 30, 2026 | $1.7B | $242M |
| Mar 31, 2026 | $1.6B | $381M |
| Dec 31, 2025 | $1.6B | $91M |
EW vs. its peers
Against 5 of its largest healthcare peers, EW's +24.1% year-to-date return beats 5 of them. None of them has done better this year.
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Edwards Lifesciences (EW) | $105.81 | +24.1% | 61.5 | BUY |
| Abbott Laboratories (ABT) | $109.29 | −12.8% | 40.8 | HOLD |
| Medtronic (MDT) | $101.61 | +5.8% | 25.0 | HOLD |
| Stryker (SYK) | $318.79 | −9.3% | 33.9 | HOLD |
| Boston Scientific (BSX) | $45.13 | −52.7% | 19.0 | HOLD |
| GE HealthCare Technologies (GEHC) | $82.60 | +0.7% | 17.5 | BUY |
EW stock: common questions
What is the EW stock price target?
27 Wall Street analysts put the average 12-month target at $112.42, in a range of $84.00–$126.00, versus a recent price of $105.81. Stock Pulse 247's model projects about $109.37 over the next month.
Is EW a buy right now?
Our AI model currently rates EW a BUY at 87% confidence. Among analysts, 25 rate it Buy or Strong Buy, 4 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has EW stock performed this year?
Year to date, EW has gained 24.1%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 25.8%, 14.3 points better than the S&P 500. The last month (+24.1%) continues the three-month advance (+14.3%).
What is EW's 52-week high and low?
EW has traded between $74.66 and $106.04 over the past 52 weeks; at $105.81 it is within 0.2% of its 52-week high of $106.04.
What sector is EW in, and who are its peers?
EW is in the healthcare sector (medical devices). Its largest peers on Stock Pulse 247 include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Boston Scientific (BSX).
How accurate is the EW forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines EW's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.